Michael Paul Pieper

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Acute Myocardial Infarction

Endoplasmic Reticulum

Acute Heart Failure

Top Venues

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. Kidney360 5 (7) (2024)
Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. Kidney360 (2024)
Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. Kidney360 5 (7) (2024)
Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. Kidney360 5 (7) (2024)
Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome. Kidney360 5 (7) (2024)
Jungmi Choi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, Aki Oomachi, Yutaro Kotobuki, Yoichi Nishiya, Michael Paul Pieper, Hiromi Imamura, Motoko Yanagita, Masamichi Yamamoto
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Communications biology 6 (1) (2023)
Jungmi Choi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, Aki Oomachi, Yutaro Kotobuki, Yoichi Nishiya, Michael Paul Pieper, Hiromi Imamura, Motoko Yanagita, Masamichi Yamamoto
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Communications biology 6 (1) (2023)
Jungmi Choi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, Aki Oomachi, Yutaro Kotobuki, Yoichi Nishiya, Michael Paul Pieper, Hiromi Imamura, Motoko Yanagita, Masamichi Yamamoto
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Communications biology 6 (1) (2023)
Jungmi Choi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, Aki Oomachi, Yutaro Kotobuki, Yoichi Nishiya, Michael Paul Pieper, Hiromi Imamura, Motoko Yanagita, Masamichi Yamamoto
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Communications biology 6 (1) (2023)